Relay Therapeutics (RLAY) Receivables (2020 - 2023)

Relay Therapeutics (RLAY) has 4 years of Receivables data on file, last reported at $211000.0 in Q3 2023.

• Receivables for Q3 2023 came in at $211000.0, down 95.88% year-over-year; the trailing twelve-month figure through Sep 2023 was $211000.0 (down 95.88% YoY), and the FY2022 annual result was $5.2 million, up 5.65% from the prior year.
• Receivables grew to $211000.0 in Q3 2023 per RLAY's latest filing, from $78000.0 in the prior quarter.
• Over five years, Receivables peaked at $82.7 million in Q4 2020 and troughed at $78000.0 in Q2 2023.
• A 4-year average of $11.2 million and a median of $5.1 million in 2021 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables rose 13.77% in 2022, then sank 98.47% in 2023.
• A 4-year view of Receivables shows it stood at $82.7 million in 2020, then sank by 94.02% to $4.9 million in 2021, then increased by 5.65% to $5.2 million in 2022, then tumbled by 95.96% to $211000.0 in 2023.
• Business Quant data shows RLAY's Receivables at $211000.0 in Q3 2023, $78000.0 in Q2 2023, and $5.2 million in Q1 2023.